Advertisement
Canada markets open in 3 hours 37 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    83.92
    +0.35 (+0.42%)
     

  • Bitcoin CAD

    87,916.46
    +707.57 (+0.81%)
     

  • CMC Crypto 200

    1,392.70
    -3.83 (-0.27%)
     

  • GOLD FUTURES

    2,360.60
    +18.10 (+0.77%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,735.00
    +167.50 (+0.95%)
     

  • VOLATILITY

    15.64
    +0.27 (+1.76%)
     

  • FTSE

    8,117.59
    +38.73 (+0.48%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Why Is Medicines Co. (MDCO) Up 2.7% Since Last Earnings Report?

Zacks Equity Research
Updated
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider WEX.

A month has gone by since the last earnings report for Medicines Co. (MDCO). Shares have added about 2.7% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Medicines Co. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.

Medicines Company’s Q2 Loss Narrows, Revenues Tank Y/Y

The Medicines Company incurred second-quarter 2018 loss of 63 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents and the year-ago loss of 72 cents.
 

ADVERTISEMENT

Quarterly revenues plunged 84.7% year over year to $1.7 million. Also, the top line missed the Zacks Consensus Estimate of $7.58 million. This downside in the quarter was mainly attributable to lower sales of Angiomax, which faces generic competition in the United States.

Adjusted research and development (R&D) expenses (excluding the impact of one-time items) increased 27.1% year over year to $26.4 million, primarily due to higher spend to support inclisiran.

Adjusted selling, general and administrative (SG&A) expenses (excluding the impact of one-time items) declined 52.4% to $15.2 million.

The company believes that its $162.5 million in cash and cash equivalents as of Jun 30, 2018 along with some fixed and non-fixed source of payments is expected to be enough to fund operations till inclisiran’s launch.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted 33.91% due to these changes.

VGM Scores

At this time, Medicines Co. has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

The company's stock is suitable solely for momentum based on our style scores.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of this revision looks promising. Notably, Medicines Co. has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
The Medicines Company (MDCO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research